Recent Quotes (30 days)

You have no recent quotes
chg | %

SQI Diagnostics Inc.  

(Public, CVE:SQD)   Watch this stock  
Find more results for SQD
0.195
+0.025 (14.71%)
Apr 28 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.19 - 0.19
52 week 0.14 - 0.42
Open 0.19
Vol / Avg. 85,000.00/51,642.00
Mkt cap 20.26M
P/E     -
Div/yield     -
EPS -0.07
Shares 103.87M
Beta 1.35
Inst. own     -
May 11, 2017
Q2 2017 SQI Diagnostics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 22, 2017
Q1 2017 SQI Diagnostics Inc Earnings Call
Feb 21, 2017
Q1 2017 SQI Diagnostics Inc Earnings Release
  

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -360.72% -354.61%
Operating margin -360.72% -354.61%
EBITD margin - -282.90%
Return on average assets -108.04% -92.97%
Return on average equity -261.23% -209.22%
Employees 36 -
CDP Score - -

Address

36 Meteor Dr
ETOBICOKE, ON M9W 1A4
Canada
+1-416-6749500 (Phone)
+1-416-6749300 (Fax)

Website links

Description

SQI Diagnostics Inc (SQI) is a Canada-based diagnostics company. The Company develops multiplexed tests and automated systems for customers needing to measure a range of biomarkers in blood or other common sample types. It offers three different platforms sqidlite, sqid x and the siqdworks to run and analyze its microarray plates. Its Ig_plex microarrays have the ability to discriminate between individual isotypes of antibodies and antigens and proteins within a single well of a microarray. Its Ig_plex CHEX technology provides multiple in-microarray checks. It has three areas of focus: Testing for the drug development industry, Animal health testing, Human disease testing or deoxyribonucleic acid (DNA) diagnostic testing. In drug development testing, SQI provides technology and equipment for blood testing in clinical trials and pre-clinical research for developing various drugs. It applies its multiplexing technology to diagnostic tests used for customers in the animal health segment.

Officers and directors

Andrew Morris President, Chief Executive Officer, Director
Patricia Lie Chief Financial Officer, Vice President of Finance and Administration
Catherine Smith Vice President - Technology
Jaymie R. Sawyer Vice President - Research & Development
Peter D. Winkley Chairman of the Board
Clive J. Beddoe Director
Age: 69
Gerald R. Connor Director
Age: 70
Wilmot L. Matthews Director
Age: 77
Allan Pronovost Ph.D. Director
Age: 56
Claude Ricks Director